

CITATION REPORT

List of articles citing

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

DOI: 10.1016/j.jalz.2011.05.2243

Alzheimer's and Dementia, 2011, 7, 386-395.e6.

Source: <https://exaly.com/paper-pdf/50444498/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 315 | Prevention trials in Alzheimer's disease: an EU-US task force report. 2011 , 95, 594-600 | | 52 |
| 314 | The future of Alzheimer's disease: the next 10 years. 2011 , 95, 718-28 | | 156 |
| 313 | Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. 2012 , 6, 455-76 | | 83 |
| 312 | Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. 2012 , 6, 365-8 | | 16 |
| 311 | Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. 2012 , 58, 787-9 | | 44 |
| 310 | Biomarker reif ff die Routine?. 2012 , 13, 19-20 | | |
| 309 | Alzheimer's disease. 2012 , 65, 329-52 | | 176 |
| 308 | Comparison of cerebrospinal fluid levels of tau and A β -42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. 2012 , 69, 1018-25 | | 84 |
| 307 | Development and advanced validation of an optimized method for the quantitation of A β 2 in human cerebrospinal fluid. 2012 , 14, 510-8 | | 32 |
| 306 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012 , 8, S1-68 | 1.2 | 368 |
| 305 | Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. <i>Alzheimer's and Dementia</i> , 2012 , 8, 520-7 | 1.2 | 29 |
| 304 | Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. <i>Alzheimer's and Dementia</i> , 2012 , 8, 445-52 | 1.2 | 37 |
| 303 | Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. 2012 , 56, 494-9 | | 8 |
| 302 | Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. 2012 , 56, 484-93 | | 64 |
| 301 | Fluid biomarkers in Alzheimer disease. 2012 , 2, a006221 | | 120 |
| 300 | Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. 2012 , 6, 419-30 | | 230 |
| 299 | Fluid biomarkers for Alzheimer's disease: standardization and recent developments. 2012 , 6, 363-4 | | 1 |

| | | |
|-----|---|----|
| 298 | Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 2. 2012 , 6, 409-17 | 66 |
| 297 | Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. 2012 , 6, 401-7 | 20 |
| 296 | Analytical aspects of molecular Alzheimer's disease biomarkers. 2012 , 6, 377-89 | 24 |
| 295 | Neurochemical dementia diagnostics for Alzheimer's disease and other dementias: an ISO 15189 perspective. 2012 , 6, 685-90 | 5 |
| 294 | Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. 2012 , 262 Suppl 2, S71-7 | 19 |
| 293 | The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. 2012 , 16, 135-41 | 20 |
| 292 | The proteomic toolbox for studying cerebrospinal fluid. 2012 , 9, 165-79 | 18 |
| 291 | The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. 2012 , 2, 211-219 | 1 |
| 290 | The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. 2012 , 1, 94-103 | |
| 289 | Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. 2012 , 16, 346-8 | 9 |
| 288 | Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. 2012 , 16, 339-45 | 31 |
| 287 | Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. 2012 , 119, 843-50 | 43 |
| 286 | Plasmin system of Alzheimer's disease patients: CSF analysis. 2012 , 119, 763-9 | 15 |
| 285 | Cerebrospinal fluid levels of $A\beta$ 2 relationship with cholinergic cortical activity in Alzheimer's disease patients. 2012 , 119, 771-8 | 24 |
| 284 | Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. 2012 , 119, 821-31 | 10 |
| 283 | CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. 2012 , 119, 861-75 | 12 |
| 282 | Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction. 2012 , 119, 735-7 | |
| 281 | Measurement of $A\beta$ -42 in cerebrospinal fluid is influenced by matrix effects. 2012 , 120, 325-33 | 29 |

| | | | |
|-----|---|-----|-----|
| 280 | Fluid biomarkers in Alzheimer's disease - current concepts. 2013 , 8, 20 | | 147 |
| 279 | Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β and total tau. 2013 , 4, | | 8 |
| 278 | Evaluation of the cerebrospinal fluid amyloid- β -42/amyloid- β -40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. 2013 , 36, 99-110 | | 37 |
| 277 | New and different approaches needed for the design and execution of Alzheimer's clinical trials. <i>Alzheimer's and Dementia</i> , 2013 , 9, 436-7 | 1.2 | 2 |
| 276 | Personalized medicine in Alzheimer's disease and depression. 2013 , 36, 616-23 | | 14 |
| 275 | Alzheimer disease: from biomarkers to diagnosis. 2013 , 169, 744-51 | | 15 |
| 274 | The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. 2013 , 263, 325-33 | | 20 |
| 273 | Progranulin peripheral levels as a screening tool for the identification of subjects with progranulin mutations in a Portuguese cohort. 2014 , 13, 214-23 | | 22 |
| 272 | Changes in amyloid- β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. 2013 , 5, 194re2 | | 125 |
| 271 | Top 20 articles cited from Alzheimer's & Dementia since 2008. <i>Alzheimer's and Dementia</i> , 2013 , 9, 619-21 ^{1,2} | | |
| 270 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013 , 9, e111-94 | 1.2 | 296 |
| 269 | CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61 | 1.2 | 289 |
| 268 | Translational proteomics in Alzheimer's disease and related disorders. 2013 , 46, 480-6 | | 17 |
| 267 | Cerebrospinal fluid biomarkers in neurological diseases in children. 2013 , 17, 7-13 | | 15 |
| 266 | Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , 2013 , 9, 160-8 | 1.2 | 16 |
| 265 | Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013 , 9, 406-13 | 1.2 | 51 |
| 264 | Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. 2013 , 75, 146-61 | | 37 |
| 263 | Utility, reliability and reproducibility of immunoassay multiplex kits. 2013 , 61, 23-9 | | 59 |

| | | | |
|-----|--|-----|-----|
| 262 | Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid- β (1-42) and β proteins as Alzheimer disease biomarkers. 2013 , 59, 903-16 | | 117 |
| 261 | Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013 , 9, 123-131.e1 | 1.2 | 82 |
| 260 | Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013 , 9, 137-140 | 1.2 | 93 |
| 259 | Metabolomics in Alzheimer's disease research. 2013 , 34, n/a-n/a | | 3 |
| 258 | What's hAPPening at synapses? The role of amyloid β protein precursor and β amyloid in neurological disorders. 2013 , 18, 425-34 | | 45 |
| 257 | A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013 , 9, 262-8 | 1.2 | 18 |
| 256 | The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. 2013 , 97, 369-76 | | 47 |
| 255 | Amyloid imaging with PET in early Alzheimer disease diagnosis. 2013 , 97, 377-98 | | 45 |
| 254 | A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. 2013 , 110, 114-23 | | 19 |
| 253 | CSF protein biomarkers predicting longitudinal reduction of CSF β amyloid42 in cognitively healthy elders. 2013 , 3, e293 | | 37 |
| 252 | A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. 2013 , 8, e67898 | | 43 |
| 251 | Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2013 , 5, 6 | 5.3 | 69 |
| 250 | Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. 2014 , 9, e100784 | | 61 |
| 249 | Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. 2014 , 2014, 1-15 | | 2 |
| 248 | CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. 2014 , 2014, 1-14 | | 11 |
| 247 | Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 47 | 5.3 | 74 |
| 246 | Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. 2014 , 55, 347-65 | | 28 |
| 245 | Preoperative cerebrospinal fluid β Amyloid/Tau ratio and postoperative delirium. 2014 , 1, 319-328 | | 36 |

| | | | |
|-----|---|-----|------|
| 244 | Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. 2014 , 6, 226ra30 | | 244 |
| 243 | A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. 2014 , 6, 38 | | 31 |
| 242 | Neuropsychiatric symptoms in the prodromal stages of dementia. 2014 , 27, 230-5 | | 36 |
| 241 | Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. 2014 , 71, 742-51 | | 35 |
| 240 | Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2014 , 10, S390-S394.e2 | 1.2 | 50 |
| 239 | Biomarkers in amyloid- β immunotherapy trials in Alzheimer's disease. 2014 , 39, 189-201 | | 54 |
| 238 | Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. 2014 , 261, 144-51 | | 45 |
| 237 | Biomarker modelling of early molecular changes in Alzheimer's disease. 2014 , 18, 213-27 | | 4 |
| 236 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. 2014 , 13, 614-29 | | 1985 |
| 235 | Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. 2014 , 52, 649-55 | | 5 |
| 234 | Editorial. <i>Alzheimer's and Dementia</i> , 2014 , 10, 590-1 | 1.2 | |
| 233 | CSF in Alzheimer's disease. 2014 , 65, 143-72 | | 18 |
| 232 | The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17 | 1.2 | 132 |
| 231 | Role of HIV in amyloid metabolism. 2014 , 9, 483-91 | | 43 |
| 230 | Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, S226-35 | 1.2 | 39 |
| 229 | Progress update: fluid and imaging biomarkers in Alzheimer's disease. 2014 , 75, 520-6 | | 18 |
| 228 | Qualification of a surrogate matrix-based absolute quantification method for amyloid- β in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. 2014 , 41, 441-51 | | 77 |
| 227 | Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 287 | 5.3 | 33 |

| | | |
|-----|---|-----|
| 226 | Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. 2015 , 21, 573-83 | 23 |
| 225 | Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. 2015 , 1346, 71-80 | 13 |
| 224 | Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. 2015 , 29, 368-81 | 23 |
| 223 | Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. 2015 , 48, 175-87 | 38 |
| 222 | Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers. 2016 , 49, 187-199 | 7 |
| 221 | Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. 2015 , 48 Suppl 1, S63-86 | 253 |
| 220 | Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. 2015 , 48, 433-41 | 28 |
| 219 | Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. 2015 , 53, e175-7 | 1 |
| 218 | Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with A β 2 and influence of disease on the total-A β 2/A β 0 ratio. 2015 , 135, 1049-58 | 14 |
| 217 | Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?. 2015 , 47, 815-43 | 58 |
| 216 | Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments. 2015 , 28, 402-9 | 28 |
| 215 | Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid- β 2, tau, and phospho-tau-181 levels. 2015 , 44, 1193-201 | 54 |
| 214 | The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. 2015 , 6, 90 | 15 |
| 213 | Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. 2015 , 6, 143 | 18 |
| 212 | Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers. 2015 , 6, 153 | 34 |
| 211 | The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. 2015 , 6, 216 | 31 |
| 210 | Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. 2016 , 49, 493-502 | 11 |
| 209 | The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. 2015 , 38, 309-22 | 9 |

| | | | |
|-----|---|-----|-----|
| 208 | Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. 2015 , 53, 453-60 | | 10 |
| 207 | Hemodynamic changes in Alzheimer's disease: A leading role behind the curtain? Commentary on "CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1123-4 | 1.2 | 1 |
| 206 | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015 , 11, 549-60 | 1.2 | 159 |
| 205 | Voices from the field: Expert reflections on mild cognitive impairment. 2015 , 14, 285-97 | | 8 |
| 204 | Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. 2015 , 129, 469-91 | | 165 |
| 203 | Independent information from cerebrospinal fluid amyloid- β and florbetapir imaging in Alzheimer's disease. 2015 , 138, 772-83 | | 169 |
| 202 | Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria. 2015 , 449, 3-8 | | 22 |
| 201 | Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. 2015 , 13, 44-7 | | 3 |
| 200 | Diagnostic Values of Cerebrospinal Fluid T-Tau and A β Using Meso Scale Discovery Assays for Alzheimer's Disease. 2015 , 45, 709-19 | | 23 |
| 199 | Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol. <i>Alzheimer's and Dementia</i> , 2015 , 11, 175-83 | 1.2 | 76 |
| 198 | The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. <i>Alzheimer's and Dementia</i> , 2015 , 11, 111-25 | 1.2 | 137 |
| 197 | 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015 , 11, e1-120 | 1.2 | 206 |
| 196 | Cerebrospinal fluid tau and amyloid- β 42 in patients with dementia. 2015 , 138, 2716-31 | | 105 |
| 195 | Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. 2015 , 36, 2587-96 | | 29 |
| 194 | Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. 2015 , 449, 9-15 | | 51 |
| 193 | Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1470-1479 | 1.2 | 12 |
| 192 | Application of the Bead-Based Technique in Neurodegeneration: A Literature Review. 2015 , 15, 281-93 | | 6 |
| 191 | Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). <i>Alzheimer's and Dementia</i> , 2015 , 11, 840-9 | 1.2 | 8 |

| | | | |
|-----|--|-----|-----|
| 190 | Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. <i>Alzheimer's and Dementia</i> , 2015 , 11, 161-74 | 1.2 | 16 |
| 189 | APOE ϵ moderates abnormal CSF- β levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. 2015 , 15, 51 | | 40 |
| 188 | CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15 | 1.2 | 87 |
| 187 | Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. 2015 , 1852, 1428-41 | | 111 |
| 186 | Amyloid biomarkers in Alzheimer's disease. 2015 , 36, 297-309 | | 320 |
| 185 | Cerebrospinal fluid A β 0 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. 2015 , 358, 308-16 | | 20 |
| 184 | Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. 2015 , 1, 455-63 | | 61 |
| 183 | How many biomarkers to discriminate neurodegenerative dementia?. 2015 , 52, 314-26 | | 14 |
| 182 | Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 58-69 | 1.2 | 271 |
| 181 | Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. 2015 , 20, 1188-96 | | 220 |
| 180 | Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. 2015 , 19, 154-63 | | 34 |
| 179 | Prognosis of Early-Onset Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. 2016 , 1, | | 11 |
| 178 | Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. 2016 , 279, 576-91 | | 48 |
| 177 | The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. 2016 , 53, 373-92 | | 6 |
| 176 | A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. 2016 , 54, 383-95 | | 31 |
| 175 | Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. 2016 , 51, 905-13 | | 12 |
| 174 | Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. 2017 , 55, 159-170 | | 19 |
| 173 | Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. 2016 , 54, 1459-1471 | | 19 |

| | | |
|-----|--|-----|
| 172 | sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. 2016 , 8, 466-76 | 256 |
| 171 | The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. 2016 , 8, 41 | 78 |
| 170 | Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. 2017 , 55, 625-644 | 33 |
| 169 | Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. 2016 , 52, 1403-13 | 11 |
| 168 | Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. 2016 , 54, 55-67 | 22 |
| 167 | Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. 2016 , 139, 2540-53 | 93 |
| 166 | Diagnostic de la maladie d'Alzheimer : apport de l'imagerie au florb β apir et autres radiopharmaceutiques de la plaque amyloïde. 2016 , 40, 364-381 | 2 |
| 165 | Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. 2016 , 8, 2243-2254 | 10 |
| 164 | Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. 2016 , 52, 51-64 | 17 |
| 163 | Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. 2016 , 6, 19393 | 155 |
| 162 | Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. 2016 , 8, 27 | 12 |
| 161 | Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. 2016 , 31, 836-47 | 38 |
| 160 | Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. 2016 , 91, 56-66 | 178 |
| 159 | Molecular Imaging in Alzheimer Clinical Trials. 2016 , 523-563 | |
| 158 | Fluid Biomarkers and Diagnostics. 2016 , 565-587 | |
| 157 | CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result. 2016 , 263, 1847-61 | 4 |
| 156 | Suspected non-Alzheimer disease pathophysiology--concept and controversy. 2016 , 12, 117-24 | 174 |
| 155 | Neuroimaging biomarkers in Alzheimer's disease and other dementias. 2016 , 30, 4-16 | 27 |

| | | | |
|-----|--|-----|-----|
| 154 | Round robin test on quantification of amyloid- β -42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016 , 12, 55-9 | 1.2 | 38 |
| 153 | Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. 2016 , 54, 1177-91 | | 48 |
| 152 | CSF A β an excellent but complicated Alzheimer's biomarker - a route to standardisation. 2017 , 467, 27-33 | | 82 |
| 151 | Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. 2017 , 641, 101-106 | | 11 |
| 150 | Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β -42 in CSF for the Diagnosis of Alzheimer's Disease. 2017 , 16, 1228-1238 | | 23 |
| 149 | Selecting A β isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. 2017 , 11, 169-178 | | 10 |
| 148 | BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. 2017 , 56, 1437-1449 | | 23 |
| 147 | Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. 2017 , 31, 13-18 | | 16 |
| 146 | Alzheimer Disease: Scientific Breakthroughs and Translational Challenges. 2017 , 92, 978-994 | | 45 |
| 145 | Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. 2017 , 57, 645-665 | | 76 |
| 144 | Clinical validity of cerebrospinal fluid A β 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. 2017 , 52, 196-213 | | 73 |
| 143 | Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. 2017 , 16, 439-446 | | 21 |
| 142 | A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. 2017 , 6, 15-24 | | 141 |
| 141 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. 2017 , 16, 661-676 | | 308 |
| 140 | Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. 2017 , 56, 885-891 | | 5 |
| 139 | Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. 2017 , 9, 84 | | 42 |
| 138 | Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. 2017 , 9, 48 | | 26 |
| 137 | Cerebrospinal Fluid Total Tau is Increased in Normal Pressure Hydrocephalus Patients who Undergo Successful Lumbar Drain Trials. 2017 , 9, e1265 | | 0 |

| | | | |
|-----|---|-----|-----|
| 136 | Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer's Disease. 2018 , 93-106 | | 1 |
| 135 | Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1460-1469 | 1.2 | 120 |
| 134 | CSF biomarkers of Alzheimer's disease concord with amyloid- β -PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1470-1481 | 1.2 | 266 |
| 133 | The Past and the Future of Alzheimer's Disease Fluid Biomarkers. 2018 , 62, 1125-1140 | | 69 |
| 132 | Concordance between brain 18F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. 2018 , 37, 3-8 | | |
| 131 | Statistical tests and identifiability conditions for pooling and analyzing multisite datasets. 2018 , 115, 1481-1486 | | 15 |
| 130 | Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. 2018 , 23, 188-197 | | 3 |
| 129 | Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. 2018 , 61, 1097-1105 | | 5 |
| 128 | Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018 , 14, 492-501 | 1.2 | 71 |
| 127 | Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. 2018 , 62, 1199-1209 | | 38 |
| 126 | Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. 2018 , 64, S647-S657 | | 5 |
| 125 | Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. 2018 , 221-252 | | 1 |
| 124 | Concordance between brain F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. 2018 , 37, 3-8 | | 2 |
| 123 | Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. 2018 , 24, 28-40 | | 13 |
| 122 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. 2018 , 19, 244-328 | | 148 |
| 121 | Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β -42 Analysis Results. 2018 , 64, 576-585 | | 76 |
| 120 | Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. 2018 , 10, 99-111 | | 4 |
| 119 | Preanalytical approaches to improve recovery of amyloid- β peptides from CSF as measured by immunological or mass spectrometry-based assays. 2018 , 10, 118 | | 4 |

| | | | |
|-----|---|-----|-----|
| 118 | Interlaboratory validation of cerebrospinal fluid β -synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. 2018 , 10, 461-470 | | 5 |
| 117 | Reappraisal of A β 0 and A β 2 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease. 2018 , 66, 219-227 | | 5 |
| 116 | Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β -amyloid 1-40 measurements. 2018 , 56, 2058-2066 | | 23 |
| 115 | The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1313-1333 | 1.2 | 61 |
| 114 | Biomarkers for Alzheimer's disease: current status and prospects for the future. 2018 , 284, 643-663 | | 278 |
| 113 | Olfactory Dysfunction as a Global Biomarker for Sniffing out Alzheimer's Disease: A Meta-Analysis. 2018 , 8, | | 25 |
| 112 | Addition of the A β 2/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. 2018 , 10, 33 | | 36 |
| 111 | How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. 2018 , 91, 395-402 | | 35 |
| 110 | Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. 2019 , 251-298 | | 1 |
| 109 | Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. 2019 , 98, 207-209 | | 9 |
| 108 | Interplay Between Macular Retinal Changes and White Matter Integrity in Early Alzheimer's Disease. 2019 , 70, 723-732 | | 5 |
| 107 | Collection and Analyses of Cerebrospinal Fluid for Pediatric Translational Research. 2019 , 98, 3-17 | | 2 |
| 106 | Lower CSF Amyloid-Beta Predicts a Higher Mortality Rate in Frontotemporal Dementia. 2019 , 9, | | 2 |
| 105 | The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. 2019 , 5, 597-609 | | 26 |
| 104 | Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease. 2019 , 2019, 7406810 | | 10 |
| 103 | Biomarker-guided clustering of Alzheimer's disease clinical syndromes. 2019 , 83, 42-53 | | 23 |
| 102 | Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. 2019 , 72, 30-38 | | 37 |
| 101 | Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [F] FDG a specific biomarker in these patients?. 2019 , 46, 1796-1805 | | 8 |

| | | | |
|-----|---|-----|-----|
| 100 | Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes. 2019 , 16, | | 9 |
| 99 | Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 74 | 5-3 | 32 |
| 98 | Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. 2019 , 68, 1151-1159 | | 6 |
| 97 | CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. 2019 , 119, 445-452 | | 13 |
| 96 | Systematic Review of miRNA as Biomarkers in Alzheimer's Disease. 2019 , 56, 6156-6167 | | 123 |
| 95 | Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. 2019 , 168, 3-23 | | 11 |
| 94 | Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy. 2019 , 11, 95 | | 9 |
| 93 | Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. 2019 , 97, 3-17 | | 51 |
| 92 | Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. 2019 , 151, 397-416 | | 18 |
| 91 | Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. 2019 , 11, 2 | | 7 |
| 90 | Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. 2020 , 27, 475-483 | | 13 |
| 89 | Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia. 2020 , 73, 597-607 | | 4 |
| 88 | CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. 2020 , 89, 55-62 | | 7 |
| 87 | APOE ϵ 4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. 2020 , 78, 587-601 | | |
| 86 | Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 272 | 5-3 | 3 |
| 85 | Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. 2020 , 2, fcaa126 | | 3 |
| 84 | Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification. 2020 , 10, 15886 | | 9 |
| 83 | Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. 2020 , 95, e3104-e3116 | | 13 |

| | | |
|----|--|-------|
| 82 | Dynamic Blood Concentrations of Aβ and Aβ in Alzheimer's Disease. 2020 , 8, 768 | 3 |
| 81 | Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. 2020 , 12, e12097 | 3 |
| 80 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. 2020 , 11, 6252 | 15 |
| 79 | Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation. 2020 , 74, 501-508 | 26 |
| 78 | A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid Aβ ₄₂ , total-tau, phospho-tau and Aβ ₄₂ in the differential diagnosis of neurodegenerative dementia. 2020 , 267, 2567-2581 | 1 |
| 77 | Developing a Clinical Biomarker Method with External Resources. 2020 , 43-50 | |
| 76 | C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. 2020 , 138, 111004 | 3 |
| 75 | Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. 2020 , 93, 144.e1-144.e15 | 6 |
| 74 | StrukturBiomarker zur Früherkennung von Morbus Alzheimer. 2020 , 26, 259-261 | |
| 73 | Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort. 2020 , 36, 696-704 | 12 |
| 72 | Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry. 2021 , 79, 573-584 | 3 |
| 71 | Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. 2021 , 34, 266-274 | 14 |
| 70 | Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 608628 | 5-3 1 |
| 69 | Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. 2021 , 13, 22 | 6 |
| 68 | Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. 2021 , 13, e12194 | 1 |
| 67 | Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. 2021 , 13, e12131 | 0 |
| 66 | Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study. 2020 , 17, 1145-1160 | 4 |
| 65 | 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. 2021 , 48, 2121-2139 | 18 |

| | | | |
|----|--|-----|----|
| 64 | The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid and tau. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1575-1582 | 1.2 | 12 |
| 63 | Can blood amyloid levels be used as a biomarker for Alzheimer's disease?. 2021 , 7, 17-25 | | 1 |
| 62 | LAG3 is not expressed in human and murine neurons and does not modulate β -synucleinopathies. | | |
| 61 | State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm. 2021 , 11, | | 4 |
| 60 | Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?. 2021 , 12, 629442 | | 7 |
| 59 | LAG3 is not expressed in human and murine neurons and does not modulate β -synucleinopathies. 2021 , 13, e14745 | | 13 |
| 58 | Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnesic Mild Cognitive Impairment Patients. 2021 , 82, 1797-1808 | | 0 |
| 57 | Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. 2021 , 159, 211-233 | | 8 |
| 56 | Recent Technological Developments in the Diagnosis and Treatment of Cerebral Edema. 2100001 | | 4 |
| 55 | Cerebrospinal Fluid MicroRNA Changes in Cognitively Normal Veterans With a History of Deployment-Associated Mild Traumatic Brain Injury. 2021 , 15, 720778 | | 1 |
| 54 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. 2021 , 11, | | 0 |
| 53 | Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. 2022 , 29, 36-46 | | 5 |
| 52 | Photonic crystal barcode: An emerging tool for cancer diagnosis. 2021 , 2, 182-195 | | 1 |
| 51 | Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. 2021 , 13, e12031 | | 0 |
| 50 | Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. 2019 , 1184, 393-405 | | 3 |
| 49 | CHAPTER 1:Introduction: Biomarkers in Translational and Personalized Medicine. 2013 , 3-39 | | 1 |
| 48 | CHAPTER 3:Introduction: The Cardinal Role of Biobanks and Human Biospecimen Collections in Biomarker Validation: Issues Impeding Impact of Biomarker Research Outcomes. 2013 , 73-110 | | 2 |
| 47 | The Mental Status Examination in Patients With Suspected Dementia. 2016 , 22, 385-403 | | 7 |

| | | |
|----|---|----|
| 46 | A First Tetraplex Assay for the Simultaneous Quantification of Total β Synuclein, Tau, β Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. 2016 , 11, e0153564 | 6 |
| 45 | The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. 2014 , 1, 181-202 | 39 |
| 44 | Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. 2015 , 2, 128-135 | 24 |
| 43 | Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. 2016 , 3, 114-120 | 31 |
| 42 | A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. 2020 , 11, | 8 |
| 41 | Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid. 2012 , 02, 176-190 | 5 |
| 40 | Platelet biomarkers in Alzheimer's disease. 2012 , 2, 95-101 | 19 |
| 39 | From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. 2021 , 9, | 0 |
| 38 | Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. 2014 , 131-157 | |
| 37 | AIImaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. 2014 , 213-254 | |
| 36 | Alzheimer's Disease and Other Neurodegenerative Disorders. 2015 , 329-351 | |
| 35 | Alzheimer's disease. 2019 , 11, 52-60 | 2 |
| 34 | Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. 2019 , 15, | |
| 33 | PET-Amyloid After Inconclusive Cerebrospinal Fluid Biomarkers in Clinical Practice. Is it Necessary to Duplicate Procedures?. 2020 , 17, 698-708 | |
| 32 | CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. 2020 , 6, e12098 | 0 |
| 31 | AIImaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. 2021 , 283-343 | |
| 30 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. 2013 , 24, 97-104 | 3 |
| 29 | Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study. 2021 , | 1 |

| | | | |
|----|---|-----|---|
| 28 | Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. 2021 , | | 2 |
| 27 | Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. 2021 , | | 2 |
| 26 | Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention.. 2021 , 74, 101544 | | 3 |
| 25 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. 2022 , | | 9 |
| 24 | Emerging Roles of Microfluidics in Brain Research: From Cerebral Fluids Manipulation to Brain-on-a-Chip and Neuroelectronic Devices Engineering.. 2022 , | | 3 |
| 23 | Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration. 1 | | |
| 22 | New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.. <i>Alzheimer's and Dementia</i> , 2022 , | 1.2 | 2 |
| 21 | Vitamin D in Alzheimer's Disease: Low Levels in Cerebrospinal Fluid Despite Normal Amounts in Serum.. 2022 , 86, 1301-1314 | | 1 |
| 20 | Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers.. 2022 , | | 0 |
| 19 | ¹⁸ F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment. | | 1 |
| 18 | Establishment of combined diagnostic models of Alzheimer's disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS). 2022 , 12, | | 1 |
| 17 | Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. 2022 , 23, 6891 | | 0 |
| 16 | The association of serum uric acid with cognitive impairment and ATN biomarkers. <i>Frontiers in Aging Neuroscience</i> , 14, | 5-3 | 0 |
| 15 | A review on comparative studies addressing exosome isolation methods from body fluids. <i>Analytical and Bioanalytical Chemistry</i> , | 4-4 | 1 |
| 14 | Potential Value of Serum Uric Acid in the Identification of Postoperative Delirium in Geriatric Patients Undergoing Knee Replacement. <i>Frontiers in Aging Neuroscience</i> , 14, | 5-3 | |
| 13 | Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. | | 0 |
| 12 | Dual PET-fMRI reveals a link between neuroinflammation, amyloid binding and compensatory task-related brain activity in Alzheimer's disease. 2022 , 5, | | |
| 11 | Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. 2022 , 1-14 | | 0 |

- 10 Whole-exome sequencing reveals PSEN1 and ATP7B combined variants as a possible cause of early-onset Lewy body dementia: a case study of genotype-phenotype correlation. ○
- 9 Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease. **2022**, ○
- 8 CSF Alzheimer Disease Biomarkers. **2022**, 99, e1640-e1650 2
- 7 Biomarkers in the cerebrospinal fluid during pregnancy. **2023**, 297-311 ○
- 6 A mink (Neovison vison) model of self-injury: Effects of CBP-CREB axis on neuronal damage and behavior. 9, ○
- 5 What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. **2023**, 54, 21-35 ○
- 4 Hemispheric Patterns of Recruitment of Object Processing Regions in Early Alzheimer's Disease: A Study Along the Entire Ventral Stream. **2022**, 1-14 ○
- 3 Neuropsychological Assessment in the Distinction Between Biomarker Defined Frontal-Variant of Alzheimer's Disease and Behavioral-Variant of Frontotemporal Dementia. **2023**, 1-10 ○
- 2 Development of a candidate reference measurement procedure by ID-LC-MS/MS for total tau protein measurement in cerebrospinal fluid (CSF). **2023**, ○
- 1 Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia. ○